Seelos Therapeutics, Inc. (SEEL )

Currency in USD Disclaimer
$1.28 -$1.17 (-47.76%)
Closed 10/15/2024
$1.15
$1.57
$1.15
$844.8

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SEEL
  • Company Seelos Therapeutics, Inc.
  • Price $1.28
  • Changes Percentage -47.76
  • Change -1.17
  • Day Low $1.15
  • Day High $1.57
  • Year High $844.8
  • Year Low $1.15
  • Market Cap $743,680
  • Price Avg 50 EMA (D) $3.96
  • Price Avg 200 EMA (D) $54.68
  • Exchange NASDAQ
  • Volume 1,667,891
  • Average Volume 533,629
  • Open $1.46
  • Previous Close $2.45
  • EPS 351.04
  • PE 0.00
  • Earnings Announcement 2024-11-12 21:00:00
  • Shares Outstanding $581,000

Company brief: SEELOS THERAPEUTICS, INC. (SEEL )

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

SEEL Corporation News

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

October 15, 2024 at 9:00 am ET

prnewswire.com -- NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for ce...

Income Statement